Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma?

Nature Clinical Practice Oncology

Volumn 6, Issue 2, 2009, Pages 64-65

  Flaherty, Keith T ^a   Sun, Weijing ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; SORAFENIB; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HEART LEFT VENTRICLE FAILURE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; MONOTHERAPY; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL;

EID: 59549085596     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1299     Document Type: Note

References (8)

1. Liu L et al. (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858
2. Schwartz JD et al. (2006) Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein [abstract]. J Clin Oncol 24 (suppl): S213
3. Zhu AX et al. (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 1898-1903
4. Sun W et al. (2007) Combination of capecitabine, oxaliplatin and bevacizumab in treatment of advanced hepatoce llular carcinoma: A phase II study [abstract]. J Clin Oncol 25: (suppl): S240
5. Abou-Alfa GK et al. (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300
6. Llovet JM et al. (2008) Sorafenib in advanced hepatocelluar carcinoma. N Engl J Med 359: 378-390
7. Cheng A et al. (2008) Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma [abstract]. J Clin Oncol 26: 4509
8. Abou-Alfa GK et al. (2008) Final results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma [abstract #128]. 2008 Gastrointestinal Cancers Symposium: 2008 January 24-27; Orlando, FL.